glp 1 approved for nash Indications GLP-1/GIP RA Summary Sheet and Beyond! The Emerging Role of Glucagon-Like

Novo Nordisk is buying three Catalent facilities for $11bn in a bid to resolve supply issues holding back growth of Ozempic for diabetes and obesity therapy Wegovy.

What Irish pharmacists need to know about Ozempic, Wegovy, Saxenda and Mounjaro: licensing, HSE reimbursement, the illegal market and patient counselling.

Get the latest updates on the Trulicity lawsuit covering eligibility criteria, potential damages, and how to file a claim against Eli Lilly and Company.

Limited evidence suggests that combined SGLT2is/GLP1-RAs therapy can potentially improve most but not all outcomes

Log in to your member account to search for covered medications.

The GLP1-RAs vs sodium-glucose cotransporter-2 (SGLT-2) inhibitors cohort included new users of GLP-1 RAs (n=83,464) or SGLT-2 inhibitors (n=78,366), and the GLP1-RAs vs dipeptidyl peptidase-4 (DPP-4) inhibitors cohort included new users of GLP-1 RAs (n=108,322) or DPP-4 inhibitors (n=55,411)